SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    L. A. Beste, G. N. Ioannou, Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs, Epidemiologic Reviews, 2015, 37, 1, 131

    CrossRef

  2. 2
    A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re, A. C. Justice, K. E. Sherman, Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings, Journal of Viral Hepatitis, 2015, 22, 6
  3. 3
    Fred Poordad, Christophe Hezode, Roger Trinh, Kris V. Kowdley, Stefan Zeuzem, Kosh Agarwal, Mitchell L. Shiffman, Heiner Wedemeyer, Thomas Berg, Eric M. Yoshida, Xavier Forns, Sandra S. Lovell, Barbara Da Silva-Tillmann, Christine A. Collins, Andrew L. Campbell, Thomas Podsadecki, Barry Bernstein, ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis, New England Journal of Medicine, 2014, 370, 21, 1973

    CrossRef

  4. 4
    Shivakumar Narayanan, Kerry Townsend, Thomas Macharia, Adrian Majid, Amy Nelson, Robert R. Redfield, Shyam Kottilil, Rohit Talwani, Anu Osinusi, Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C, Hepatology International, 2014, 8, 4, 560

    CrossRef

  5. 5
    Sammy Saab, Christian Jackson, MD, FACG, Jose Nieto, DO, FACG, FACP, Fritz Francois, MD, MSc, FACG, Hepatitis C in African Americans, The American Journal of Gastroenterology, 2014, 109, 10, 1576

    CrossRef

  6. 6
    Conrado M. Fernández Rodriguez, Maria Luisa Gutierrez Garcia, Impacto del tratamiento antiviral en la historia natural del virus de la hepatitis C, Gastroenterología y Hepatología, 2014, 37, 10, 583

    CrossRef

  7. 7
    Sebhat Erqou, Arpan Mohanty, Pashtoon Murtaza Kasi, Adeel A. Butt, Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection, ISRN Gastroenterology, 2014, 2014, 1

    CrossRef

  8. 8
    Z. M. Younossi, F. Kanwal, S. Saab, K. A. Brown, H. B. El-Serag, W. R. Kim, A. Ahmed, M. Kugelmas, S. C. Gordon, The impact of hepatitis C burden: an evidence-based approach, Alimentary Pharmacology & Therapeutics, 2014, 39, 5
  9. 9
    Elamin H. Elbasha, Jagpreet Chhatwal, Shannon A. Ferrante, Antoine C. El Khoury, Pedro A. Laires, Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal, Applied Health Economics and Health Policy, 2013, 11, 1, 65

    CrossRef

  10. You have free access to this content10
    S. L. Szeinbach, R. W. Baran, B. Dietz, L. Gazzouola Rocca, D. Littlefield, B. P. Yawn, Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument, Alimentary Pharmacology & Therapeutics, 2013, 37, 5
  11. You have free access to this content11
    Brian R. Edlin, Hepatitis C screening: Getting it right, Hepatology, 2013, 57, 4
  12. 12
    S. Erqou, A. Mohanty, K. A. McGinnis, G. Vanasse, M. S. Freiberg, K. E. Sherman, A. A. Butt, Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia, Journal of Viral Hepatitis, 2013, 20, 7
  13. 13
    Faleh Z. Alfaleh, Khalid Alswat, Ahmed Helmy, Waleed Al-hamoudi, Mohamed El-sharkawy, Mohanned Omar, Ahmed Shalaby, Mohaned A. Bedewi, Qais Hadad, Safiyya M. Ali, Ahmad Alfaleh, Ayman A. Abdo, The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy, Liver International, 2013, 33, 6
  14. 14
    Arpan Mohanty, Sebhat Erqou, Kathleen A. McGinnis, Gary Vanasse, Matthew S. Freiberg, Kenneth E. Sherman, Adeel A. Butt, Therapy for Hepatitis C Virus Infection Increases Survival of Patients With Pretreatment Anemia, Clinical Gastroenterology and Hepatology, 2013, 11, 6, 741

    CrossRef

  15. 15
    A. A. Butt, F. Kanwal, Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients, Clinical Infectious Diseases, 2012, 54, 1, 96

    CrossRef

  16. 16
    P. O. Coffin, J. D. Scott, M. R. Golden, S. D. Sullivan, Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C, Clinical Infectious Diseases, 2012, 54, 9, 1259

    CrossRef

  17. 17
    K. E. Nelson, The Impact of Chronic Hepatitis C Virus Infection on Mortality, Journal of Infectious Diseases, 2012, 206, 4, 461

    CrossRef

  18. 18
    Adeel A. Butt, Kathleen McGinnis, Melissa Skanderson, Amy C. Justice, A Comparison of Treatment Eligibility for Hepatitis C Virus in HCV-Monoinfected Versus HCV/HIV-Coinfected Persons in Electronically Retrieved Cohort of HCV-Infected Veterans, AIDS Research and Human Retroviruses, 2011, 27, 9, 973

    CrossRef

  19. 19
    Lisa I. Backus, Derek B. Boothroyd, Barbara R. Phillips, Pamela Belperio, James Halloran, Larry A. Mole, A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C, Clinical Gastroenterology and Hepatology, 2011, 9, 6, 509

    CrossRef

  20. 20
    Sumio Watanabe, Nobuyuki Enomoto, Kazuhiko Koike, Namiki Izumi, Hajime Takikawa, Etsuko Hashimoto, Fuminori Moriyasu, Hiromitsu Kumada, Michio Imawari, Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis, Hepatology Research, 2011, 41, 10
  21. 21
    Jeffrey S. McCombs, Yong Yuan, Janet Shin, Sammy Saab, Economic Burden Associated With Patients Diagnosed With Hepatitis C, Clinical Therapeutics, 2011, 33, 9, 1268

    CrossRef

  22. 22
    A. A. Butt, T. Umbleja, J. W. Andersen, R. T. Chung, K. E. Sherman, The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin, Alimentary Pharmacology & Therapeutics, 2011, 33, 11
  23. 23
    Yalena Amador-Cañizares, Santiago Dueñas-Carrera, Early Interferon-Based Treatment After Detection of Persistent Hepatitis C Virus Infection: A Critical Decision, Journal of Interferon & Cytokine Research, 2010, 30, 11, 817

    CrossRef

  24. 24
    J Michael Estep, Zobair M Younossi, Hepatitis C and metabolic syndrome, Expert Review of Endocrinology & Metabolism, 2010, 5, 2, 209

    CrossRef

  25. 25
    Tahany Awad, Kristian Thorlund, Goran Hauser, Davor Stimac, Mahasen Mabrouk, Christian Gluud, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials, Hepatology, 2010, 51, 4
  26. 26
    Eric Chak, Sammy Saab, Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response, Current Hepatitis Reports, 2010, 9, 3, 147

    CrossRef

  27. 27
    Changhyun Roh, Ho-Young Lee, Sang-Eun Kim, Sung-Kee Jo, Quantum-dots-based detection of hepatitis C virus (HCV) NS3 using RNA aptamer on chip, Journal of Chemical Technology and Biotechnology, 2010, 85, 8
  28. 28
    Ramsey Cheung, Ajitha Mannalithara, Gurkirpal Singh, Utilization and Antiviral Therapy in Patients with Chronic Hepatitis C: Analysis of Ambulatory Care Visits in the US, Digestive Diseases and Sciences, 2010, 55, 6, 1744

    CrossRef

  29. 29
    Mieke H Lamers, Mark Broekman, Joost PH Drenth, Christian Gluud, Aminoadamantanes versus other antiviral drugs for chronic hepatitis C, The Cochrane Library,
  30. 30
    Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud, Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C, The Cochrane Library,
  31. 31
    Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud, Lise Lotte Gluud, Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C, The Cochrane Library,